Loading..

PTC Therapeutics, Inc. (PTCT) Report Analysis

Corporate Events

Positive

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to ...

2022-06-24 00:00:00

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2000 Value Index

Positive

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to ...

2022-06-24 00:00:00

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 3000 Value Index

Positive

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to ...

2022-06-24 00:00:00

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2500 Value Index

Positive

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to ...

2022-06-24 00:00:00

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell Small Cap Comp Value Index

Positive

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to ...

2022-06-24 00:00:00

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 3000E Value Index

Neutral

PTC Therapeutics, Inc. has filed a Shelf Regist...

2022-06-23 00:00:00

PTC Therapeutics, Inc. has filed a Shelf Registration in the amount of $305.2695 million. Security Name: Common Stock Securities Offered: ...

Neutral

PTC Therapeutics, Inc. Presents at 2022 Annual ...

2022-06-21 13:11:00

PTC Therapeutics, Inc. Presents at 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun-23-2022 . Venue: Scottsdale, Arizon...

Neutral

PTC Therapeutics, Inc. - Special Call

2022-06-20 20:00:00

To review topline results from Study 041 of Translarna(TM) (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy

Neutral

PTC Therapeutics to Relocate Its Corporate Headquarters

2022-06-10 12:51:00

PTC is relocating its corporate headquarters from South Plainfield, N.J. to a newfacility at Warren Corporate Center. The lease spans two full...

Negative

PTC Therapeutics, Inc. Appoints Alethia Young t...

2022-06-09 12:00:00

PTC Therapeutics, Inc. announced the election of Alethia Young to the company's Board of Directors. Ms. Young has more than 20 years of experi...

Neutral

Parent Project Muscular Dystrophy, 2022 Annual ...

2022-06-09 05:00:00

Parent Project Muscular Dystrophy, 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun 23, 2022 through Jun 26, 2022. Venu...

Neutral

Parent Project Muscular Dystrophy, 2022 Annual ...

2022-06-09 05:00:00

Parent Project Muscular Dystrophy, 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun 23, 2022 through Jun 26, 2022. Venu...

Neutral

PTC Therapeutics, Inc. Presents at William Blai...

2022-06-06 12:00:00

PTC Therapeutics, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-09-2022 02:20 PM. Venue: Loews Chicago Hotel,...

Positive

PTC Therapeutics, Inc. Announces Preliminary Re...

2022-06-03 12:00:00

PTC Therapeutics, Inc. announced encouraging preliminary safety and efficacy results from its Phase 1B study of unesbulin (PTC596) in advanced...

Neutral

PTC Therapeutics, Inc. Presents at The 2022 ASC...

2022-06-03 00:00:00

PTC Therapeutics, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-04-2022 01:15 PM. Venue: McCormick Place, Chicago, Illinois, United States.

Positive

PTC Therapeutics, Inc. Announces FDA Approves L...

2022-05-31 05:00:00

PTC Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi (risdiplam) to in...

Neutral

PTC Therapeutics, Inc. - Special Call

2022-05-20 12:09:00

To discuss the positive opinion from the CHMP on its AADC deficiency gene therapy, Upstaza

Positive

PTC Therapeutics, Inc. Receives Positive CHMP O...

2022-05-20 12:08:00

PTC Therapeutics, Inc. announced that Upstaza received a positive opinion from the Committee for Medicinal Products for Human Use of the Europ...

Neutral

PTC Therapeutics, Inc. Presents at Gene Therapy...

2022-05-12 06:51:00

PTC Therapeutics, Inc. Presents at Gene Therapy Analytical Development Europe, Jun-01-2022 11:00 AM. Venue: London, United Kingdom.

Neutral

PTC Therapeutics, Inc. Provides Earnings Guidan...

2022-05-03 20:01:00

PTC Therapeutics, Inc. provided earnings guidance for 2022. For the period the company anticipates total revenues to be between $700 and $750 ...

Neutral

PTC Therapeutics, Inc. Presents at RBC Capital ...

2022-04-29 20:30:00

PTC Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-18-2022 02:05 PM. Venue: InterContinental New York, B...

Neutral

PTC Therapeutics, Inc., Annual General Meeting,...

2022-04-28 20:15:00

PTC Therapeutics, Inc., Annual General Meeting, Jun 08, 2022, at 09:00 Eastern Daylight. Agenda: To elect the four class iii director nominees...

Neutral

PTC Therapeutics, Inc. - Shareholder/Analyst Call

2022-04-28 20:15:00

AGM

Neutral

PTC Therapeutics, Inc., Q1 2022 Earnings Call, ...

2022-04-19 12:00:00

PTC Therapeutics, Inc., Q1 2022 Earnings Call, May 03, 2022

Neutral

PTC Therapeutics, Inc. to Report Q1, 2022 Resul...

2022-04-19 12:00:00

PTC Therapeutics, Inc. announced that they will report Q1, 2022 results on May 03, 2022

Positive

PTC Therapeutics, Inc. Provides Update on EMA R...

2022-04-14 12:30:00

PTC Therapeutics, Inc. announced that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatm...

Neutral

PTC Therapeutics, Inc. has closed its Shelf Reg...

2022-04-13 00:00:00

PTC Therapeutics, Inc. has closed its Shelf Registration dated January 05, 2022 in the amount of $143.185 million. Security Name: Common St...

Neutral

Hanson Wade Limited, Gene Therapy Analytical De...

2022-04-06 17:15:00

Hanson Wade Limited, Gene Therapy Analytical Development Europe, May 30, 2022 through Jun 01, 2022. Venue: London, United Kingdom.

Neutral

Hanson Wade Limited, 2nd Gene Therapy Medical A...

2022-04-06 17:15:00

Hanson Wade Limited, 2nd Gene Therapy Medical Affairs Summit, Apr 19, 2022 through Apr 21, 2022. Venue: Boston, Massachusetts, United States.

Neutral

PTC Therapeutics, Inc. Presents at 2nd Gene The...

2022-04-06 17:15:00

PTC Therapeutics, Inc. Presents at 2nd Gene Therapy Medical Affairs Summit, Apr-19-2022 . Venue: Boston, Massachusetts, United States. Speaker...

Neutral

Hanson Wade Limited, 2nd Annual Gene Therapy Pa...

2022-04-06 17:15:00

Hanson Wade Limited, 2nd Annual Gene Therapy Patient Engagement Summit, Jun 07, 2022 through Jun 09, 2022. Venue: Boston, Massachusetts, Unit...

Neutral

PTC Therapeutics, Inc. Presents at 2nd Annual G...

2022-04-06 17:15:00

PTC Therapeutics, Inc. Presents at 2nd Annual Gene Therapy Patient Engagement Summit, Jun-07-2022 . Venue: Boston, Massachusetts, United State...

Neutral

PTC Therapeutics, Inc. Presents at Global Pharm...

2022-04-03 04:24:00

PTC Therapeutics, Inc. Presents at Global Pharmaceutical Regulatory Affairs Summit, Apr-12-2022 03:20 PM. Speakers: Ana Tempestini, Associate ...

Neutral

PTC Therapeutics, Inc. Presents at Advanced The...

2022-04-01 16:04:00

PTC Therapeutics, Inc. Presents at Advanced Therapies Congress & Expo 2022 Virtual Conference, May-24-2022 12:50 PM. Venue: London, United Kin...

Positive

PTC Therapeutics, Inc. Announces Initiation of ...

2022-03-30 20:00:00

PTC Therapeutics, Inc. announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with Huntington's disease (...

Neutral

Terrapinn Holdings Ltd, Advanced Therapies Cong...

2022-03-30 15:35:00

Terrapinn Holdings Ltd, Advanced Therapies Congress & Expo 2022 Virtual Conference, May 24, 2022 through May 25, 2022. Venue: London, United Kingdom.

Neutral

PTC Therapeutics, Inc. Presents at Bank of Amer...

2022-03-22 05:03:00

PTC Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 05:20 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd....

Neutral

RBC Capital Markets, LLC, RBC Capital Markets G...

2022-03-04 01:06:00

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New Yor...

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

William Blair & Company, L.L.C., William Blair’...

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chi...

Neutral

Informa plc, Global Pharmaceutical Regulatory A...

2022-01-17 00:00:00

Informa plc, Global Pharmaceutical Regulatory Affairs Summit, Apr 06, 2022 through Apr 13, 2022.

Positive

Oral Splicing Modifiers Systemically Lower Hunt...

2021-12-20 13:00:00

PTC Therapeutics, Inc. announced the Nature Communications publication characterizing the novel splicing mechanism induced by compounds identi...

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Neutral

PTC Therapeutics, Inc. Presents at 4th Annual E...

2021-11-16 13:00:00

PTC Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 08:25 AM.

Positive

PTC Therapeutics, Inc. Revises Revenue Guidance...

2021-10-28 20:00:00

PTC Therapeutics, Inc. revised revenue guidance for the full year 2021. The company now anticipates net product revenues for the DMD franchise...

Positive

PTC Therapeutics, Inc. Announces Expansion of T...

2021-10-25 12:00:00

PTC Therapeutics, Inc. announced that the Brazilian National Health Surveillance Agency, ANVISA has approved the expansion of the indication o...

Neutral

PTC Therapeutics, Inc. to Report Q3, 2021 Resul...

2021-10-24 23:31:00

PTC Therapeutics, Inc. announced that they will report Q3, 2021 results at 4:30 PM, Eastern Daylight on Oct 28, 2021

Neutral

PTC Therapeutics, Inc., Q3 2021 Earnings Call, ...

2021-10-14 12:58:00

PTC Therapeutics, Inc., Q3 2021 Earnings Call, Oct 28, 2021

Positive

PTC Therapeutics Celebrates Opening of Gene The...

2021-10-14 12:30:00

PTC Therapeutics, Inc. announces the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. The Hopewell gene thera...

Neutral

PTC Therapeutics, Inc. Presents at 30th Annual ...

2021-10-01 10:34:00

PTC Therapeutics, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 08:00 AM. Venue: Rancho Palos Verdes, Californ...

Neutral

PTC Therapeutics, Inc. Presents at Longwood Hea...

2021-09-28 18:44:00

PTC Therapeutics, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-05-2021 11:40 AM. Speakers: Stuart W. Peltz, Co-Founder, CEO & ...

Neutral

Longwood Fund, Longwood Healthcare Leaders Conf...

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Neutral

PTC Therapeutics, Inc. - Special Call

2021-09-20 20:34:00

To provide an update on the PTC518 Phase 2 study, to be conducted in Huntington's disease patients, which PTC expects to initiate by the end o...

Positive

PTC Therapeutics, Inc. Announces STRIDE Data Sh...

2021-09-20 12:30:00

PTC Therapeutics, Inc. presented real-world results from the STRIDE patient registry demonstrating that treatment with Translarna™ (ataluren) ...

Neutral

PTC Therapeutics, Inc. Presents at Morgan Stanl...

2021-08-27 12:02:00

PTC Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 11:00 AM. Venue: New Windsor, United States.

Neutral

PTC Therapeutics, Inc. Presents at Cantor Globa...

2021-08-27 12:02:00

PTC Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 03:20 PM. Venue: New York, United States.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

PTC Therapeutics, Inc. Announces Waylivra Appro...

2021-08-23 20:30:00

PTC Therapeutics, Inc. announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved ...

Positive

PTC Therapeutics, Inc. Raises Revenue Guidance ...

2021-07-29 20:00:00

PTC Therapeutics, Inc. raised revenue guidance for the full year of fiscal 2021. For the year, the company expects net product revenues for th...

Neutral

PTC Therapeutics, Inc. Presents at Cell & Gene ...

2021-07-29 02:31:00

PTC Therapeutics, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 . Venue: Carlsbad, California, United States. Speakers: Matthe...

Neutral

PTC Therapeutics, Inc. to Report Q2, 2021 Resul...

2021-07-15 12:00:00

PTC Therapeutics, Inc. announced that they will report Q2, 2021 results After-Market on Jul 29, 2021

Neutral

PTC Therapeutics, Inc., Q2 2021 Earnings Call, ...

2021-07-15 12:00:00

PTC Therapeutics, Inc., Q2 2021 Earnings Call, Jul 29, 2021

Positive

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2000 Value Index

2022-06-24 00:00:00

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2000 Value Index

Positive

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 3000 Value Index

2022-06-24 00:00:00

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 3000 Value Index

Positive

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2500 Value Index

2022-06-24 00:00:00

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2500 Value Index

Positive

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell Small Cap Comp Value Index

2022-06-24 00:00:00

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell Small Cap Comp Value Index

Positive

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 3000E Value Index

2022-06-24 00:00:00

PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 3000E Value Index

Neutral

PTC Therapeutics, Inc. has filed a Shelf Registration in the amount of $305.2695 million.

2022-06-23 00:00:00

PTC Therapeutics, Inc. has filed a Shelf Registration in the amount of $305.2695 million. Security Name: Common Stock Securities Offered: 8,475,000 Transaction Features: ESOP Related Offering

Neutral

PTC Therapeutics, Inc. Presents at 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun-23-2022

2022-06-21 13:11:00

PTC Therapeutics, Inc. Presents at 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun-23-2022 . Venue: Scottsdale, Arizona, United States.

Neutral

PTC Therapeutics, Inc. - Special Call

2022-06-20 20:00:00

To review topline results from Study 041 of Translarna(TM) (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy

Neutral

PTC Therapeutics to Relocate Its Corporate Headquarters

2022-06-10 12:51:00

PTC is relocating its corporate headquarters from South Plainfield, N.J. to a newfacility at Warren Corporate Center. The lease spans two fullbuildings located at 400 and 500 Warren Corporate Center Drive and, following construction, will include offices, collaboration and conferencing spaces, and research laboratories. The facility will provide flexible and innovative workspaces with the capacity needed to support PTC's long-term growth of its expanding pipeline of products.

Negative

PTC Therapeutics, Inc. Appoints Alethia Young to its Board of Directors

2022-06-09 12:00:00

PTC Therapeutics, Inc. announced the election of Alethia Young to the company's Board of Directors. Ms. Young has more than 20 years of experience in healthcare and biotech equity research and investing. She is currently the Chief Financial Officer of Graphite Bio where she oversees the company's finance, investor relations and corporate communications functions, and plays a key role in overall corporate strategy. Prior to her role at Graphite Bio, Ms. Young worked at Cantor Fitzgerald as senior biotech analyst and head of research, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies. Prior to joining Cantor Fitzgerald, Ms. Young held senior biotech analyst positions at Credit Suisse and Deutsche Bank. Earlier in her career, she was a research policy analyst and president at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan in the investment banking and asset management divisions. She earned a B.A. in economics and Spanish from Duke University. She currently serves on the Board of Directors for BUILD NYC.

Neutral

Parent Project Muscular Dystrophy, 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun 23, 2022 through Jun 26, 2022

2022-06-09 05:00:00

Parent Project Muscular Dystrophy, 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun 23, 2022 through Jun 26, 2022. Venue: Scottsdale, Arizona, United States.

Neutral

Parent Project Muscular Dystrophy, 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun 23, 2022 through Jun 26, 2022

2022-06-09 05:00:00

Parent Project Muscular Dystrophy, 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD), Jun 23, 2022 through Jun 26, 2022. Venue: Scottsdale, Arizona, United States.

Neutral

PTC Therapeutics, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-09-2022 02:20 PM

2022-06-06 12:00:00

PTC Therapeutics, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-09-2022 02:20 PM. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.

Positive

PTC Therapeutics, Inc. Announces Preliminary Results Presented At ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

2022-06-03 12:00:00

PTC Therapeutics, Inc. announced encouraging preliminary safety and efficacy results from its Phase 1B study of unesbulin (PTC596) in advanced leiomyosarcoma (LMS) patients. The results demonstrated that treated patients achieved an 18.2 percent objective response rate and a 51.5% disease control rate. In addition, unesbulin was generally well tolerated. The results from the dose escalation study which evaluated unesbulin in combination with dacarbazine (DTIC), will be presented on Saturday, June 4, during the Sarcoma Oral Abstract Session beginning at 1:15 p.m. CDT at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The primary objectives of the study were to determine the recommended Phase 2 dose (RP2D) of unesbulin in combination with DTIC and to characterize the safety profile of the combination. In addition, the secondary objectives included progression free survival and duration of response. Unesbulin 300 mg taken twice a week in combination with DTIC 1,000 mg/m2 every 21 days was established as the RP2D. Based on the preliminary data from the Phase 1B study, PTC has initiated the SUNRISE LMS study. SUNRISE LMS is an international, placebo-controlled, registration-directed study comparing the efficacy and safety of unesbulin and DTIC versus placebo and DTIC in patients with advanced LMS who have received =1 prior line of systemic therapy.

Neutral

PTC Therapeutics, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-04-2022 01:15 PM

2022-06-03 00:00:00

PTC Therapeutics, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-04-2022 01:15 PM. Venue: McCormick Place, Chicago, Illinois, United States.

Positive

PTC Therapeutics, Inc. Announces FDA Approves Label Extension for Evrysdi for Infants with Spinal Muscular Atrophy Under 2 Months Old

2022-05-31 05:00:00

PTC Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi (risdiplam) to include infants under 2 months old with spinal muscular atrophy (SMA). The approval is based on interim efficacy and safety data from the RAINBOWFISH study in newborns, which showed that pre-symptomatic babies treated with Evrysdi achieved key milestones, such as sitting and standing, with half walking after 12 months of treatment. All infants were alive at 12 months without permanent ventilation. Evrysdi is designed to treat SMA by increasing and sustaining the production of the SMN protein, which is found throughout the body and is critical for maintaining healthy motor neurons and movement. Evrysdi was based on PTC's splicing platform. Evrysdi is marketed by Roche and in the United States by Genentech, a member of the Roche Group. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.

Neutral

PTC Therapeutics, Inc. - Special Call

2022-05-20 12:09:00

To discuss the positive opinion from the CHMP on its AADC deficiency gene therapy, Upstaza

Positive

PTC Therapeutics, Inc. Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency

2022-05-20 12:08:00

PTC Therapeutics, Inc. announced that Upstaza received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Once ratified by the European Commission, Upstaza will be the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase deficiency for patients 18 months and older and the first marketed gene therapy directly infused into the brain. The CHMP opinion is based on the findings of clinical studies conducted in Taiwan. In addition, data from the compassionate use treatment of patients in Europe were included in the application. In the clinical studies, patients went from no display of any motor milestone development to developing clinically meaningful motor skills and neuromuscular function from as early as three months following treatment, with transformational improvements shown to continue up to nine years after treatment.1 Cognitive and communication skills improved in all treated patients. PTC expects the European Commission to ratify the marketing authorization for Upstaza under exceptional circumstances in approximately two months. The decision will be applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.

Neutral

PTC Therapeutics, Inc. Presents at Gene Therapy Analytical Development Europe, Jun-01-2022 11:00 AM

2022-05-12 06:51:00

PTC Therapeutics, Inc. Presents at Gene Therapy Analytical Development Europe, Jun-01-2022 11:00 AM. Venue: London, United Kingdom.

Neutral

PTC Therapeutics, Inc. Provides Earnings Guidance for 2022

2022-05-03 20:01:00

PTC Therapeutics, Inc. provided earnings guidance for 2022. For the period the company anticipates total revenues to be between $700 and $750 million. PTC anticipates net product revenues for the DMD franchise for full year 2022 to be between $475 and $495 million.

Neutral

PTC Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-18-2022 02:05 PM

2022-04-29 20:30:00

PTC Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference, May-18-2022 02:05 PM. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.

Neutral

PTC Therapeutics, Inc., Annual General Meeting, Jun 08, 2022

2022-04-28 20:15:00

PTC Therapeutics, Inc., Annual General Meeting, Jun 08, 2022, at 09:00 Eastern Daylight. Agenda: To elect the four class iii director nominees nominated by board of directors and named in the proxy statement, each to serve for a term ending in 2025, or until his or her successor has been duly elected and qualified; to approve the company’s amended and restated 2013 long-term incentive plan; to ratify the appointment of ernst & young llp, a registered public accounting firm, as independent registered public accounting firm for the fiscal year ending December 31, 2022; to hold an advisory vote to approve named executive officer compensation; to hold an advisory vote on the frequency of the advisory vote to approve named executive officer compensation; and to transact such other business as may properly come before the annual meeting or any adjournment or postponement thereof.

Neutral

PTC Therapeutics, Inc. - Shareholder/Analyst Call

2022-04-28 20:15:00

AGM

Neutral

PTC Therapeutics, Inc., Q1 2022 Earnings Call, May 03, 2022

2022-04-19 12:00:00

PTC Therapeutics, Inc., Q1 2022 Earnings Call, May 03, 2022

Neutral

PTC Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

2022-04-19 12:00:00

PTC Therapeutics, Inc. announced that they will report Q1, 2022 results on May 03, 2022

Positive

PTC Therapeutics, Inc. Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program

2022-04-14 12:30:00

PTC Therapeutics, Inc. announced that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficiency (PTC-AADC) with the Committee for Advanced Therapies (CAT). The CAT is responsible for the scientific assessment of advanced therapies based on its expert member's assessment of the quality, safety and efficacy of the product. The CAT is scheduled to provide a draft opinion for adoption to the Committee for Medicinal Products for Human Use (CHMP) in May 2022. If approved, PTC's AADC gene therapy would be the first marketed gene therapy directly infused into the brain. The AADC gene therapy Marketing Authorization Application is supported by the findings of three clinical studies conducted in Taiwan. In addition, data from the compassionate use treatment of two patients in Europe were included in the application. PTC-AADC administration occurs through a stereotactic surgical procedure, a minimally invasive neurosurgical procedure used for the treatment of a number of pediatric and adult neurological disorders. PTC-AADC, is a one-time gene replacement therapy currently under regulatory review in Europe for the treatment of AADC deficiency. It is a recombinant adeno-associated virus serotype 2 (AAV2)-based gene therapy, containing the human DDC gene.i It is designed to correct the underlying genetic defect, by delivering a functioning DDC gene directly into the putamen, increasing the AADC enzyme and restoring dopamine production.

Neutral

PTC Therapeutics, Inc. has closed its Shelf Registration dated January 05, 2022 in the amount of $143.185 million.

2022-04-13 00:00:00

PTC Therapeutics, Inc. has closed its Shelf Registration dated January 05, 2022 in the amount of $143.185 million. Security Name: Common Stock Securities Offered: 3,500,000 Transaction Features: ESOP Related Offering

Neutral

Hanson Wade Limited, Gene Therapy Analytical Development Europe, May 30, 2022 through Jun 01, 2022

2022-04-06 17:15:00

Hanson Wade Limited, Gene Therapy Analytical Development Europe, May 30, 2022 through Jun 01, 2022. Venue: London, United Kingdom.

Neutral

Hanson Wade Limited, 2nd Gene Therapy Medical Affairs Summit, Apr 19, 2022 through Apr 21, 2022

2022-04-06 17:15:00

Hanson Wade Limited, 2nd Gene Therapy Medical Affairs Summit, Apr 19, 2022 through Apr 21, 2022. Venue: Boston, Massachusetts, United States.

Neutral

PTC Therapeutics, Inc. Presents at 2nd Gene Therapy Medical Affairs Summit, Apr-19-2022

2022-04-06 17:15:00

PTC Therapeutics, Inc. Presents at 2nd Gene Therapy Medical Affairs Summit, Apr-19-2022 . Venue: Boston, Massachusetts, United States. Speakers: Inha Kim, Executive Director, Medical Affairs, Northern Europe.

Neutral

Hanson Wade Limited, 2nd Annual Gene Therapy Patient Engagement Summit, Jun 07, 2022 through Jun 09, 2022

2022-04-06 17:15:00

Hanson Wade Limited, 2nd Annual Gene Therapy Patient Engagement Summit, Jun 07, 2022 through Jun 09, 2022. Venue: Boston, Massachusetts, United States.

Neutral

PTC Therapeutics, Inc. Presents at 2nd Annual Gene Therapy Patient Engagement Summit, Jun-07-2022

2022-04-06 17:15:00

PTC Therapeutics, Inc. Presents at 2nd Annual Gene Therapy Patient Engagement Summit, Jun-07-2022 . Venue: Boston, Massachusetts, United States. Speakers: Paula Orandash, Patient Engagement Liaison, Community Education Gene Therapy.

Neutral

PTC Therapeutics, Inc. Presents at Global Pharmaceutical Regulatory Affairs Summit, Apr-12-2022 03:20 PM

2022-04-03 04:24:00

PTC Therapeutics, Inc. Presents at Global Pharmaceutical Regulatory Affairs Summit, Apr-12-2022 03:20 PM. Speakers: Ana Tempestini, Associate Director - LATAM, Regulatory Affairs.

Neutral

PTC Therapeutics, Inc. Presents at Advanced Therapies Congress & Expo 2022 Virtual Conference, May-24-2022 12:50 PM

2022-04-01 16:04:00

PTC Therapeutics, Inc. Presents at Advanced Therapies Congress & Expo 2022 Virtual Conference, May-24-2022 12:50 PM. Venue: London, United Kingdom. Speakers: Axel Boehnke, Director Market Access EU North.

Positive

PTC Therapeutics, Inc. Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease

2022-03-30 20:00:00

PTC Therapeutics, Inc. announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with Huntington's disease (HD). PIVOT-HD is a global trial starting in the United States. PTC518 is an oral, small molecule splicing modifier that was specifically designed to selectively lower huntingtin mRNA and protein. There are no current treatments for the underlying cause of HD. The PIVOT-HD Phase 2 clinical trial is designed in two parts: an initial 12-week placebo-controlled phase focused on PTC518 pharmacology and pharmacodynamic effect, followed by a 9-month placebo-controlled phase focused on PTC518 biomarker effect.

Neutral

Terrapinn Holdings Ltd, Advanced Therapies Congress & Expo 2022 Virtual Conference, May 24, 2022 through May 25, 2022

2022-03-30 15:35:00

Terrapinn Holdings Ltd, Advanced Therapies Congress & Expo 2022 Virtual Conference, May 24, 2022 through May 25, 2022. Venue: London, United Kingdom.

Neutral

PTC Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 05:20 PM

2022-03-22 05:03:00

PTC Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 05:20 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Matthew B. Klein, Chief Operating Officer.

Neutral

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022

2022-03-04 01:06:00

RBC Capital Markets, LLC, RBC Capital Markets Global Healthcare Conference, May 17, 2022 through May 18, 2022. Venue: InterContinental New York, Barclay hotel, New York, New York, United States.

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.

Neutral

Informa plc, Global Pharmaceutical Regulatory Affairs Summit, Apr 06, 2022 through Apr 13, 2022

2022-01-17 00:00:00

Informa plc, Global Pharmaceutical Regulatory Affairs Summit, Apr 06, 2022 through Apr 13, 2022.

Positive

Oral Splicing Modifiers Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform

2021-12-20 13:00:00

PTC Therapeutics, Inc. announced the Nature Communications publication characterizing the novel splicing mechanism induced by compounds identified from the Huntington Disease (HD) program. These splicing modifiers were discovered through PTC's innovative splicing platform and were shown to specifically and selectively lower huntingtin protein through the modulation of pre-messenger RNA splicing. HD is a rare, inherited disease that causes the progressive degeneration of nerve cells in the brain, impacting a person's functional abilities. While HD can present at any age, it is most prevalent in people 30 to 50 years old. It affects approximately 45,000 people in?the United States. HD is caused by a mutation in the huntingtin gene, which is responsible for creating huntingtin protein (HTT).?As time progresses, the mutated huntingtin protein forms clumps in the brain cells, resulting in damaged cells and eventually cell death. There are no treatments for the underlying cause of HD.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Neutral

PTC Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 08:25 AM

2021-11-16 13:00:00

PTC Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 08:25 AM.

Positive

PTC Therapeutics, Inc. Revises Revenue Guidance for the Full Year 2021

2021-10-28 20:00:00

PTC Therapeutics, Inc. revised revenue guidance for the full year 2021. The company now anticipates net product revenues for the DMD franchise for the full year 2021 to be between $400 million and $420 million from previous guidance of $370 million and $390 million.

Positive

PTC Therapeutics, Inc. Announces Expansion of Translarna Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil

2021-10-25 12:00:00

PTC Therapeutics, Inc. announced that the Brazilian National Health Surveillance Agency, ANVISA has approved the expansion of the indication of Translarna to include ambulatory children aged 2 to 5 years old with nonsense mutation Duchenne muscular dystrophy. This broadens the use beyond the previous age range of 5 years and older. Duchenne is a severe progressive disease that leads to rapidly worsening muscle function with children often using a wheelchair by early adolescence and eventually requiring artificial ventilation to breathe. Translarna is the only treatment for the underlying cause of Duchenne caused by a nonsense mutation. Clinical trials and real-world evidence have demonstrated Translarna's potential to slow disease progression and improve patient outcomes.

Neutral

PTC Therapeutics, Inc. to Report Q3, 2021 Results on Oct 28, 2021

2021-10-24 23:31:00

PTC Therapeutics, Inc. announced that they will report Q3, 2021 results at 4:30 PM, Eastern Daylight on Oct 28, 2021

Neutral

PTC Therapeutics, Inc., Q3 2021 Earnings Call, Oct 28, 2021

2021-10-14 12:58:00

PTC Therapeutics, Inc., Q3 2021 Earnings Call, Oct 28, 2021

Positive

PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility

2021-10-14 12:30:00

PTC Therapeutics, Inc. announces the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. The Hopewell gene therapy manufacturing center complements PTC's existing operations at the Company's global headquarters in South Plainfield, N.J. and brings the total number of New Jersey-based employees to 625.

Neutral

PTC Therapeutics, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 08:00 AM

2021-10-01 10:34:00

PTC Therapeutics, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 08:00 AM. Venue: Rancho Palos Verdes, California, United States. Speakers: Stuart W. Peltz, Co-Founder, CEO & Executive Director.

Neutral

PTC Therapeutics, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-05-2021 11:40 AM

2021-09-28 18:44:00

PTC Therapeutics, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-05-2021 11:40 AM. Speakers: Stuart W. Peltz, Co-Founder, CEO & Executive Director.

Neutral

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Neutral

PTC Therapeutics, Inc. - Special Call

2021-09-20 20:34:00

To provide an update on the PTC518 Phase 2 study, to be conducted in Huntington's disease patients, which PTC expects to initiate by the end of the year

Positive

PTC Therapeutics, Inc. Announces STRIDE Data Show Translarna Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy

2021-09-20 12:30:00

PTC Therapeutics, Inc. presented real-world results from the STRIDE patient registry demonstrating that treatment with Translarna™ (ataluren) delays loss of ambulation by more than five years in boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) compared to standard of care (SoC) alone. Pulmonary function decline was also delayed by 1.8 years in those treated with Translarna and SoC. A time-to-event analysis of five years of registry data, presented at the World Muscle Society (WMS) 2021 Virtual Congress, shows that boys treated with Translarna plus SoC had a median age of loss of ambulation of 17.9 years old compared with 12.5 years old for those on SoC alone. At 12 years old, 80% of boys receiving Translarna plus SoC are still walking, compared to 52% of the boys receiving SoC alone. The median age that boys treated with Translarna reached a predicted forced vital capacity (FVC) lower than 60% was 17.6 years old, compared with 15.8 years old for those who did not receive Translarna. This delay in loss of lung function is critical, as the sub-60% threshold is considered the milestone at which patients usually start to require respiratory physical therapy. The data was compared with natural history from a propensity-score matched cohort in a long-term natural history study (the Cooperative International Neuromuscular Research Group (CINRG) natural history database of Duchenne patients). Translarna continues to be well tolerated in nmDMD patients, and the safety results, representing 1059 patient-years of exposure, remain consistent with the therapy's known safety profile.

Neutral

PTC Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 11:00 AM

2021-08-27 12:02:00

PTC Therapeutics, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 11:00 AM. Venue: New Windsor, United States.

Neutral

PTC Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 03:20 PM

2021-08-27 12:02:00

PTC Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 03:20 PM. Venue: New York, United States.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

PTC Therapeutics, Inc. Announces Waylivra Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome

2021-08-23 20:30:00

PTC Therapeutics, Inc. announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra (volanesorsen) as the first treatment for familial chylomicronemia syndrome (FCS) in Brazil. FCS is a rare genetic disease which results in significant disease burden to patients including potentially fatal pancreatitis and chronic complications due to permanent organ damage. ANVISA's approval of Waylivra is based on results from the Phase 3 APPROACH study and the APPROACH Open-Label Extension study and is supported by results from the Phase 3 COMPASS study. Results from the Phase 3 APPROACH trial, the largest study ever conducted in patients with FCS, show that treatment with Waylivra reduced triglycerides 94% when compared to placebo. All patients in the trial maintained a low-fat diet. Waylivra is a self-administered, subcutaneous injection that comes in a single-use, prefilled syringe and is the first approved pharmacotherapy indicated for the treatment of FCS. It is an innovative antisense oligonucleotide (ASO), with a novel mode of action designed to reduce the production of apolipoprotein C-III (Apoc-III), a protein that slows down the breakdown of fats called apolipoprotein C-III. By blocking the production of this protein, the medicine reduces the level of triglycerides in the blood and, as a result, fat accumulation in the body, which is expected to reduce the risk of pancreatitis.

Positive

PTC Therapeutics, Inc. Raises Revenue Guidance for the Full Year of Fiscal 2021

2021-07-29 20:00:00

PTC Therapeutics, Inc. raised revenue guidance for the full year of fiscal 2021. For the year, the company expects net product revenues for the DMD franchise for the full year 2021 to be between $370 and $390 million.

Neutral

PTC Therapeutics, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021

2021-07-29 02:31:00

PTC Therapeutics, Inc. Presents at Cell & Gene Meeting on the Mesa, Oct-12-2021 . Venue: Carlsbad, California, United States. Speakers: Matthew B. Klein, Chief Development Officer.

Neutral

PTC Therapeutics, Inc. to Report Q2, 2021 Results on Jul 29, 2021

2021-07-15 12:00:00

PTC Therapeutics, Inc. announced that they will report Q2, 2021 results After-Market on Jul 29, 2021

Neutral

PTC Therapeutics, Inc., Q2 2021 Earnings Call, Jul 29, 2021

2021-07-15 12:00:00

PTC Therapeutics, Inc., Q2 2021 Earnings Call, Jul 29, 2021

Fundamental Summary

When PTC Therapeutics released their Q1 data on 2022-05-03, their results were relatively underwhelming. This is because taken individually, their growth and income factors looked positive and healthy. But when looking at the overall picture of these results compared to their peers proved less remarkable. We give PTC Therapeutics a 59 rating and a UNDERPERFORM recommendation.

PTC Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 148.74 million compared to USD 117.94 million a year ago. Net loss was USD 126.73 million compared to USD 128.64 million a year ago. Basic loss per share from continuing operations was USD 1.78 compared to USD 1.83 a year ago.

Business Description

PTC Therapeutics, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company’s splicing platform includes PTC518, which is being developed for the treatment of Huntington’s disease. PTC Therapeutics has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Sector Overview

PTC Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. PTC Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 1,799.6 -7.1% 61
Liabilities 1,890.2 -2.4% 57
Price to Book -23.9 -101.2% 37
Cash & Equivalents 144.2 -24.0% 49
Equity -90.6 -6399.1% 80
EBITDA -276.9 4.3% 78
Total Revenues 569.4 5.7% 54
Parameter Value Change Score
Return on Equity -516.8 -138.4% 66
Net Cashflow -2.5 87.1% 72
Capital Expenditure -31.9 -12.9% 54
Asset Turnover 0.3 12.1% 83
Free Cashflow -5.6 -17.0% 53

* All values are TTM

The below chart reflects PTC Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While PTC Therapeutics's peer average final assessment score stands on 61.0, PTC Therapeutics's score is 59.

  •  PTCT
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 23 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 25 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 27 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. PTC Therapeutics's stock is now priced above its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the near, medium, and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), PTC Therapeutics's stock indicates that it's likely oversold. Overall, these technical indicators signal positive upward momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 78.

Bullish 78
Close Price 39.94
52W Low 25.6
52W High 45.23
5D MA 39.27
50D MA 33.2
200D MA 37.49
MACD 1.92
RSI 8.96
STOCH 98.08

Balance Sheet Analysis

PTC Therapeutics's most recent balance sheet report was not encouraging. PTC Therapeutics publishes discouraging results related to book value factors in this report. As of the current filing, price to book ratio (P/B) was reported as -23.9, representing a -101.2% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. The company's book value factors were lackluster and showed that management hasn't figured out how to overperform expectations. Disappointing results in book value factors typically precede negative pressure in stock prices, so its book value factors received a grade of 37. Also, PTC Therapeutics reported concerning cash and cash equivalents metrics in this filing. Specifically, they reported that cash and cash equivalents were 144.2, representing a -24.0% change from the last period. This performance is significantly less impressive than its peers and competitors. Consequently, their cash and cash equivalents movement received a grade of 49. On the other hand, Equity, jumped out as looking rather positive. PTC Therapeutics produced great equity metrics for this filing, demonstrating management's skill in increasing shareholder value. PTC Therapeutics's equity was reported as -90.6, which represents a -6399.1% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. These equity changes appear exceptionally balanced and impressive objectively compared to their peers. Consequently, their equity movement received a grade of 80. Therefore, it received a cautionary score of 51.

Parameter Value Change Score
Assets 1,799.6 -7.1% 61
Liabilities 1,890.2 -2.4% 57
Price to Book -23.9 -101.2% 37
Cash & Equivalents 144.2 -24.0% 49
Equity -90.6 -6399.1% 80
* All values are TTM

The below chart describes PTC Therapeutics's performance as reflected on its balance sheet with respect to its peers. While PTC Therapeutics received a balance sheet score of 51, the average of its peers stands on 63.0.

  •  PTCT
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 23 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 25 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 27 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

PTC Therapeutics appears likely to maintain its strong income statement metrics and momentum going forward. PTC Therapeutics's management was effective in improving its EBIDTA, which now sits at -276.9 and represents a 4.3% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. The company is headed in the right direction regarding EBITDA, exhibiting efficient capital controls and strong overall financial performance. The company's EBITDA movement, therefore, received a grade of 78. Also, In this filing, PTC Therapeutics reported a return on equity (ROE) ratio of -516.8, which represents a change of -138.4%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Consequently, their return factors received a grade of 66. At the same time, one critical income statement metric, Revenue Efficiency, was notably weak. PTC Therapeutics's revenue efficiency metrics look especially concerning this period, highlighting issues management is having controlling and reducing expenses while increasing earnings. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. Consequently, their revenue efficiency received a grade of 54. Therefore, we scored its income statement a 73.

Parameter Value Change Score
EBITDA -276.9 4.3% 78
Total Revenues 569.4 5.7% 54
Return on Equity -516.8 -138.4% 66
* All values are TTM

The below chart describes PTC Therapeutics's performance as reflected on its income statement with respect to its peers. While PTC Therapeutics received a income statement score of 73 , the average of its peers stands on 61.0.

  •  PTCT
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
Insmed Incorporated 2.4B 51 58 73 57 23 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 25 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 27 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Two main cash flow metrics, Asset Turnover and Net Cash Flow, are driving the positive outlook for PTC Therapeutics's financial strength. PTC Therapeutics's published asset turnover numbers were encouraging and reflected management's balanced change strategy. PTC Therapeutics recorded asset turnover of 0.3, which represents a 12.1% change from the previous report. This metric might have a 4.1 percent impact on companies in the same industry and with the same market capitalization. Its asset turnover metrics are especially remarkable relative to their peers. We believe the stock price has room to grow to reflect its intrinsic value accurately. Correspondingly, their asset turnover movement received a grade of 83. Also, PTC Therapeutics presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of -2.5, which is a change of 87.1% from the last filing. The company is headed in the right direction regarding business priorities, exhibiting prudent net cash flow management and growth. Consequently, their net cash flow movement received a grade of 72. That said, one metric, Free Cash flow, stood out as particularly concerning. PTC Therapeutics did a poor job related to generating and maintaining strong free cash flow this period, which stood at -5.6, representing a -17.0% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 2.6 percent by this parameter. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Its free cash flow movement, therefore, received a grade of 53. Its cash flow received an overall score of 72.

Parameter Value Change Score
Net Cashflow -2.5 87.1% 72
Capital Expenditure -31.9 -12.9% 54
Asset Turnover 0.3 12.1% 83
Free Cashflow -5.6 -17.0% 53
* All values are TTM

The below chart describes PTC Therapeutics's performance as reflected on its cash flow with respect to its peers. While PTC Therapeutics received a cash flow score of 72, the average of its peers stands on 67.0.

  •  PTCT
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
Insmed Incorporated 2.4B 79 80 61 89 82 23 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 25 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 27 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.